Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone out there slapping EOD? If so, thanks :)
What are some examples of future innovation in your eyes?
I keep coming back to how this product is too good for the company to ever go under. I mean, it's truly revolutionary. Imagine if Microsoft never got off its feet...
SAN DIEGO--(BUSINESS WIRE)--Feb. 18, 2009--
Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has completed
a 30-day treatment case study to further evaluate the safety and
efficacy of the Aethlon Hemopurifier® as a candidate treatment for
Hepatitis-C Virus (HCV) infection. The Hemopurifier® is a first-in-class
medical device that assists the immune response in combating infectious
disease through real-time therapeutic filtration of infectious viruses
and immunosuppressive proteins. As in previous studies, which
demonstrated robust viral load reductions resulting from three
Hemopurifier® treatments administered in a one-week trial, the study
enrolled an HCV patient suffering from end-stage renal disease (ESRD)
requiring regular kidney dialysis treatment. The study goal was to
further demonstrate the Aethlon Hemopurifier® inhibits the progression
of HCV in infected ESRD patients. The study protocol provided for 12
Hemopurifier(R) treatments to be administered during the patient’s
normally scheduled dialysis treatment. As a result, a 4-hour
Hemopurifier® treatment was administered thrice weekly over a period of
30 days. There were no observed adverse events were reported in any of
the treatments. The study was conducted at the Fortis Hospital in Delhi,
India. Aethlon will disclose viral load and associated data upon receipt
from testing laboratories. The insight obtained from the study will help
define future clinical protocols and early commercialization strategies.
The study data may also be utilized to expand the scope of an IDE
submission to the FDA to include the potential use of the Hemopurifier®
in the United States as a device designed for the single-use removal of
HCV from blood. At present, the focus of Aethlon’s IDE submission has
been directed towards high risk bioterror and emerging pandemic threats.
It is estimated that up to 20% of the 1.6 million global ESRD population
is infected with HCV. Beyond the treatment of infected ESRD patients,
the overall opportunity for the Hemopurifier® is HCV care is
significant, as approximately 180 million people worldwide (3% of the
world's population) are HCV infected. According to the World Health
Organization (WHO), only 30-50% of infected patients will beneficially
respond to the 48-week pegylated interferon-ribavirin treatment standard.
“While we still have much work ahead, I am proud that our research and
clinical programs allow us the opportunity to expand the therapeutic
filtration industry beyond kidney dialysis and into the much larger
infectious disease and cancer markets,” stated Aethlon Chairman and CEO,
Jim Joyce. “The continued demonstration of Hemopurifier® safety and
effectiveness increases the likelihood that our technology will be
available to extend and improve the lives of those suffering from these
horrific conditions,” concluded Joyce.
In a previous studies conducted the Fortis Hospital, six ESRD patients
received a series of three, 4-hour Hemopurifier® treatments every other
day during the course of one week. The treatment regimen also mirrored
the patient's normal kidney dialysis schedule, allowing for the
inclusion of the Hemopurifier® without disrupting dialysis treatment.
Robust viral load reductions were observed in three HCV patients who
completed the three-treatment protocol. Patient #1 had a 95% reduction
three days post treatment and 89% reduction seven days post treatment.
Patient #2 had a 85% reduction three days post treatment and 50%
reduction seven days post treatment, and patient #3 had a 60% reduction
three days post treatment and 83% reduction seven days post treatment.
Aethlon additionally disclosed that it soon expects the receipt of viral
load and blood chemistry data resulting from a recently completed 30-day
HIV treatment case study. The Hemopurifier® is the first medical device
to target the treatment of both HIV and HCV, as well as a broad-spectrum
of other infectious viral pathogens.
Nice, thanks for the preliminary report. That's part of my homework this evening.. I don't remember that paragraph from the last one, which I read pretty carefully.
For now, back to trying to cure schizophrenia.
That's what I'm saying... ultimately doesn't matter what we call it if it keeps selling like we all think it's selling! :)
All good stuff Mustang, but you left part of it out:
"We thank you for your patience as the timing of such growth is determined by events at store level."
I'm not saying proceed with caution... just saying watch the speed limit, if you will... even if it is 160 around a track.
Nice post... agree 100%..
We can all take a page from Eric and be responsible shareholders much like he's a responsible CEO...
The way I see it, even if it is a '100% roll out' over time, if it doesn't sell in the first few regions, Lowes won't continue to put it in new stores (unless they reveal a specific contract for a certain number of regions or stores in the PR). It's ALWAYS being tested. So I just think we should be careful in saying for sure it's going to be in every Lowes by the end of the year, for instance.
Ultimately, what we call it is semantics as long as the product sells well, which I wholeheartedly think will be the case.
Just look at the snuggie. ;) eom
Didn't someone say something about mid february?
...... :)
No, I read every post, everyday.
Definitely agree it's huge news :)
Thanks for clarifying. Again I hope you're right, but why start with a very specific, single zipcode? It just seems too specific. It seems like a 'roll out' would start with several zipcodes (say 5 out of ~43,000 total in the states.. would still be relatively small scale, no?).
I hope it's a roll out, though, I'm all in and can't wait to see the product(s) in the local MA Lowes.
Hey Mustang, I hope you're right.. I'm definitely long here as is evident in my posting history, but I'm just wondering about this sentence from the website announcement:
"We thank you for your patience as the timing of such growth is determined by events at store level."
What do you suppose this means?
Agree that they're testing a market to learn how to do it right and to see how well it sells. It will require a lot of patience from us longs to see WC all across america, but most of us know first hand how well the product works. It's just a matter of time.
Oh, just EOD yesterday.. sorry to alert you :)
ouch.
the LOGOS? Do they have different ones that have 'canada' on them? Does anyone have a screenshot of what it used to look like before?
Seems to me, those logos at least, are the same as before, unless I'm remembering incorrectly (I hope I am) or you were talking about somewhere else where it actually READS just 'wal mart' or 'hopme depot' without the 'canada' tacked on.
Good eye if I'm wrong, though.
I loved the news, but it looks like the market is waiting for something else....
Is the PR hinting that WNBD is making the products available to the armed forces at a discount?
Don't take this the wrong way, I love our forces, but I love a high profit margin too :)
I think the important news for us here is in the exposure we'll get.
SAN DIEGO--(BUSINESS WIRE)--
Aethlon Medical, Inc. (OTCBB:AEMD) announced today that its Chairman and
CEO, James A. Joyce will give a company presentation at the Equities
2009 Conference on February 16th at 10:30am PST and 3:30pm
PST. Mr. Joyce will also host one-on-one meetings at the conference on
February 17th. To schedule a meeting with Mr. Joyce, contact
Ross Dimaggio at (609) 433-6711 or by email: ross@nortiacapital.com.
The conference will be held at Bally's Hotel and Casino in Las Vegas,
Nevada. Additional information can be accessed online at: www.smallcapconferences.com.
Nice look, thanks for sharing... Feb is going to be exciting :)
Ah, of course, the wiki... soapy's masterpiece. Should've known.
Anyone have the link to the youtube promotional video for potential merchants? I don't see it in the ibox and I'm not sure if I can find the correct one on youtube...
I'd like to forward some info to the owner of a 3-store hardware chain in MA.
Thanks in advance,
Steve
This release seems to suggest they have some cash (or shares?) to throw around.
SAN DIEGO--(BUSINESS WIRE)--Jan. 27, 2009--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has appointed
Prashant Mehta, Ph.D. to the newly created Director of Business
Development position. Dr. Mehta has extensive biotechnology and
financial industry experience, and since 2006 has been Managing Director
of Gemini Strategies LLC, a manager of small-cap institutional funds
with investments in the life science and medical device industry.
"I am very excited to join the Aethlon team and look forward to
developing and delivering strategic initiatives that unwrap the immense
potential of the Hemopurifier(R) to benefit patients and our investors,"
stated Dr. Mehta.
Dr. Mehta was previously an investment banker at Granite Financial
Group, Inc., and a Principal at TSG Partners, where he developed
corporate strategies for life science, diagnostic, biotechnology and
medical device companies. Dr. Mehta has also served as Director of
Business Development and Research at Imgenex Corp., was a member of the
Bioinformatics Project Management group at Diversa Corp., and a
Scientist at Nanogen, Inc. and the Department of Neuropharmacology at
The Scripps Institute. Dr. Mehta completed his Postdoctoral Fellowship
at Duke University focusing on molecular biology of DNA replication.
"Prashant's unique spectrum of expertise allows him to confidently
navigate the science, business, and financial industry," stated Jim
Joyce, Chairman and CEO of Aethlon Medical. "His presence will further
increase the opportunities we have to leverage our Hemopurifier(R)
platform technology to establish business relationships in the United
States and abroad," concluded Joyce.
Dr. Mehta holds numerous degrees including a Ph.D. in Biochemistry from
the Indian Institute of Science in Bangalore, India; an M.Sc. in
Microbiology from M.S. University of Baroda in Baroda, India; and a
B.Sc. in Microbiology from Bombay University in Bombay, India.
I have a crock pot cook off this Friday at work... any suggestions?
Apparently the markey didn't get goosebumps.. hopefully it will in mid feb.
Maybe I'll take my PURO money over here...
lol, I haven't done anything here since the party came, and I don't have time to moderate a full-time forum. Definitely a lot of upside from .06 though....
Mod job will be available shortly, good luck all, hope you all made some $ :)
Ah, ok.. missed this:
"Initial viral load and immune cell data
resulting from the study are expected to be available for disclosure in
mid-February."
WHY do they keep talking about the past studies? Talk about THIS one! Just one sentence on it.
Unless there was no statistically significant reduction in viral load...?
They completed the study..
Aethlon Medical Inc. has added a news release to its Investor Relations website.
Title: Aethlon Medical Completes First Medical Device Study to Treat HIV/AIDS
Date: 1/26/2009 9:19:00 AM
For a complete listing of our news releases, please click here
SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2009--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has completed
the "first-in-man" study of a medical device to treat Human
Immunodeficiency Virus (HIV), the disease that causes Acquired Immune
Deficiency Syndrome (AIDS). In the study, an HIV-infected individual
completed a twelve treatment study of the Aethlon Hemopurifier(R)
administered thrice weekly over the course of 30-days. The Hemopurifier(R)
is a therapeutic filtration device that serves as an artificial adjunct
to the immune system. In HIV care the Hemopurifier(R) targets the
clearance of all circulating strains of infectious HIV, including those
varieties that cause patients to fail antiviral drug regimens.
Additionally, the device assists to preserve immune response through the
removal of gp120 and other toxic proteins shed by HIV to kill-off immune
cells, the hallmark of AIDS. The study was conducted at the Sigma New
Life Hospital in Punjab, India. Initial viral load and immune cell data
resulting from the study are expected to be available for disclosure in
mid-February.
"Based on previous treatment outcomes in Hepatitis-C patients, we are
cautiously optimistic that the data resulting from our first HIV study
will also prove to be positive," stated Jim Joyce, Chairman and CEO of
Aethlon Medical. "The principal investigator of our study has reported
all twelve Hemopurifier(R) treatments were completed without any observed
adverse events, and that the patient feels an improved sense of well
being, including increased energy and appetite," concluded Joyce.
In a previous infectious disease study, treatment with the Hemopurifier(R)
resulted in robust viral load reductions in Hepatitis-C (HCV) infected
patients who completed a treatment protocol of three, 4-hour
Hemopurifier(R) treatments every other day during the course of one week.
The Study was conducted at the Fortis Hospital in Delhi, India.
Patient #1 had a 95% reduction three days post treatment and 89%
reduction seven days post treatment. The initial viral load for patient
1 was 5.3 x 10(5) viral units per ml of blood (IU/ml). Patient 1's viral
load seven days post treatment was 5.7 x 10(4) IU/ml.
Patient #2 had a 85% reduction three days post treatment and 50%
reduction seven days post treatment. The initial viral load for patient
2 was 9.2 x 10(6) IU/ml. Patient 2's viral load seven days post
treatment was 4.6 x 10(6) IU/ml.
Patient #3 had a 60% reduction three days post treatment and 83%
reduction seven days post treatment. The initial viral load for patient
3 was 3.0 x 10(8) IU/ml. Patient 3's viral load seven days post
treatment was 5.1 x 10(7) IU/ml. All viral load measurements were
performed with real-time quantitative polymerase chain reaction
(RT-PCR). Control samples were measured in duplicate while treatment
samples were generally measured in triplicate.
I agree.. sooner than later, imo
I think it's just saying all those cities are larger... Toronto is the 5th largest after those four. Our day will come for those four cities, too, though.
Looks like we're testing recent lows this week
Yeah, that's the hope I suppose, and how I wanted to read it :).
Guess no one liked the HIV news this morning... I must admit it seemed a little extraneous.
Good day all... I smell news today, not sure why. Just feels like a money-making day, doesn't it?